Pharma BD Deal Intelligence
This was not an acquisition — it was Abbott's 2004 spin-off of its Hospital Products Division into standalone Hospira, which grew into the #1 generic-injectables/biosimilars player before a decade of severe quality failures forced a 2015 sale to Pfizer for $17B
Full analysis, sources & comparables →Crain's reported that on April 12, 2004 'Abbott sets terms for Hospira spinoff,' with Hospira to assume $700 million of Abbott's debt and pay $300 million for…
PR Newswire confirms Christopher B. Begley was "the company's founding CEO, overseeing Hospira's 2004 spin-off from Abbott Laboratories" and led it through the…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Spinoff terms set April 12; Hospira independent May 3 2004; ~$2.5B annual sales, 14,000 employees, 14 manufacturing sites
This was not an acquisition — it was Abbott's 2004 spin-off of its Hospital Products Division into standalone Hospira, which grew into the #1 generic-injectables/biosimilars player before a decade of severe quality failures forced a 2015 sale to Pfizer for $17B
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Hospira Inc. / Abbott Hospital Products Division (this deal) | 2004 | — | 54 |
| Hospira Inc. / Javelin Pharmaceuticals, Inc. | 2010 | $145M | 25 |
| Hospira Inc. / Orchid Chemicals & Pharmaceuticals (Generic Injectables Business) | 2010 | $400M | 23 |
| Hospira Inc. / Orchid Chemicals & Pharmaceuticals Ltd. (API and R&D facilities) | 2012 | $200M | 22 |
| Hospira Inc. / Orchid Chemicals & Pharmaceuticals Ltd. (Generic Injectables business) | 2009 | $400M | 22 |
| UCB SA / Celltech Group plc | 2004 | $2.7B | 92 |
| Yamanouchi Pharmaceutical / Fujisawa Pharmaceutical Co. Ltd. | 2004 | $7.6B | 84 |
← Browse all deals · How we score deals
More: 2004 deals · Hospira Inc. deals